In short
Tovorafenib, also known as DAY101, is an oral type II RAF kinase inhibitor being investigated in several clinical trials for the treatment of pediatric low-grade gliomas and other solid tumors with alterations in the MAPK pathway. This article summarizes key information about ongoing clinical trials evaluating tovorafenib's safety and efficacy in various patient populations.
At a glance
- Drug Name
- Tovorafenib (DAY101)
- Drug Class
- Oral type II RAF kinase inhibitor
- Primary Indications
- Pediatric low-grade gliomas, solid tumors with MAPK pathway alterations
- Administration
- Oral, typically once weekly
- Key Clinical Trials
- NCT05566795, NCT04985604, NCT05828069
- Primary Outcomes
- Overall response rate (ORR), Progression-free survival (PFS)
- Secondary Outcomes
- Duration of response, Overall survival, Safety and tolerability
- Patient Populations
- Children and young adults with various solid tumors, focus on RAF-altered tumors
- Combination Therapies
- Being studied alone and in combination with other therapies (e.g., vinblastine, pimasertib)
What is Tovorafenib?
Tovorafenib, also known as DAY101, Ojemda, TAK580, or AMG-2112819, is a new medication being studied for the treatment of various types of cancer. It belongs to a class of drugs called RAF inhibitors, which target specific proteins involved in cancer growth.
How Does Tovorafenib Work?
Tovorafenib works by blocking enzymes called RAF kinases, which are part of a pathway in cells known as the MAPK pathway. This pathway is often overactive in cancer cells, causing them to grow and divide uncontrollably. By inhibiting these enzymes, Tovorafenib may help slow down or stop the growth of cancer cells.
What Conditions Does Tovorafenib Treat?
Tovorafenib is being studied for the treatment of several types of cancer, including:
- Low-grade gliomas: These are slow-growing brain tumors that typically occur in children and young adults.
- Melanoma: A type of skin cancer.
- Langerhans cell histiocytosis (LCH): A rare disease where certain white blood cells build up in various organs, causing damage.
- Craniopharyngioma: A rare type of brain tumor that typically affects children and young adults.
- Other solid tumors with specific genetic alterations in the MAPK pathway.
How is Tovorafenib Administered?
Tovorafenib is taken orally, usually as a tablet or a powder that is mixed with water to form a liquid. The exact dosing schedule can vary depending on the specific clinical trial, but it is often given once weekly.
Current Clinical Trials
Tovorafenib is currently being studied in several clinical trials:
- A study comparing Tovorafenib to standard chemotherapy for children with low-grade gliomas.
- A trial testing Tovorafenib in combination with other drugs for various solid tumors.
- A study of Tovorafenib for patients with Langerhans cell histiocytosis.
- A trial combining Tovorafenib with another drug called nivolumab for craniopharyngioma.
Potential Side Effects
As Tovorafenib is still in clinical trials, all of its potential side effects are not yet known. The ongoing studies are closely monitoring patients for any adverse events. It's important to note that side effects can vary from person to person, and not everyone will experience the same effects. If you're participating in a clinical trial, your healthcare team will closely monitor you for any side effects and provide appropriate care.